AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6347278 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + cyclophosphamide/methotrexate/5‐fluorouracil (CMF) for 12 monthly cycles
Number of subjects: 805
Study 6347278 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 805
Study 6347278 — intervention group
Group type: EXPERIMENTAL
Intervention: C
Number of subjects: 805
Study 6347278 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 805
Study 31752838 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance of adverse events (AEs) through retrospective record review and post-operative visit observations.
Number of subjects: 5352
Study 31752838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid dispensation as a proxy for VMMC-related infections.
Number of subjects: 5352
Study 29846836 — intervention group
Group type: EXPERIMENTAL
Intervention: Savings‐led economic empowerment intervention
Number of subjects: 0
Study 29846836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26975815 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 40
Study 26975815 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 40
Study 25457690 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Support (FFS) program
Number of subjects: 46
Study 21507661 — intervention group
Group type: EXPERIMENTAL
Intervention: PMDI
Number of subjects: 87
Study 19328435 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg b.i.d. celecoxib (Celebrex, Pfizer)
Number of subjects: 2528
Study 19328435 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg b.i.d. naproxen sodium (Aleve, Bayer)
Number of subjects: 2528
Study 19328435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2528
Study 19328435 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (celecoxib, naproxen, placebo)
Number of subjects: 2528
Study 17138635 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training (VT) applied at 50 Hz for 1 min on quadriceps, hamstring, and calf muscles
Number of subjects: 50
Study 17138635 — intervention group
Group type: COMPARATOR
Intervention: Non-vibration training (non-VT)
Number of subjects: 50
Study 15103227 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM‐23745
Number of subjects: 16
Study 15103227 — intervention group
Group type: COMPARATOR
Intervention: octreotide
Number of subjects: 16
Study 11453317 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated OSA
Number of subjects: 38
Study 11453317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 38
Study 11453317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 38
Study 11453317 — intervention group
Group type: COMPARATOR
Intervention: nCPAP (control for OSA)
Number of subjects: 38
Study 11453317 — intervention group
Group type: COMPARATOR
Intervention: Normal night of sleep (control for sleep deprivation)
Number of subjects: 38
Study 11453317 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (control for alcohol ingestion)
Number of subjects: 38
Study 9744120 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweat patches
Number of subjects: 48
Study 9744120 — intervention group
Group type: COMPARATOR
Intervention: Control period (urine testing)
Number of subjects: 48
Study 8113844 — intervention group
Group type: EXPERIMENTAL
Intervention: NVB-P (vinorelbine and cisplatin)
Number of subjects: 612
Study 8113844 — intervention group
Group type: EXPERIMENTAL
Intervention: VDS-P (vindesine and cisplatin)
Number of subjects: 612
Study 8113844 — intervention group
Group type: COMPARATOR
Intervention: NVB (vinorelbine alone)
Number of subjects: 612
Study 2462221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 6
Study 2462221 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg)
Number of subjects: 6
Study 2462221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30467742 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg once every other week (QOW) dosing by intravenous infusion
Number of subjects: 23
Study 30467742 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg QOW dosing regimen
Number of subjects: 23
Study 30467742 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or 8 mg/kg once every 4 weeks dosing
Number of subjects: 23
Study 28820468 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 19.8 mg with Pegylated-Interferon-α2b and Ribavirin
Number of subjects: 60
Study 28820468 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Pegylated-Interferon-α2b and Ribavirin
Number of subjects: 60
Study 24470389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planned reconstruction
Number of subjects: 19
Study 24470389 — intervention group
Group type: COMPARATOR
Intervention: Conventional free form reconstruction
Number of subjects: 19
Study 24470389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planned reconstruction (mandibular body)
Number of subjects: 19
Study 24470389 — intervention group
Group type: COMPARATOR
Intervention: Conventional free form reconstruction (mandibular body)
Number of subjects: 19
Study 24367864 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening for prostate cancer
Number of subjects: 0
Study 21085891 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 8 cmH₂O
Number of subjects: 18
Study 21085891 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 12 cmH₂O
Number of subjects: 18
Study 21085891 — intervention group
Group type: COMPARATOR
Intervention: CPAP sham (3 cmH₂O)
Number of subjects: 18
Study 21085891 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 5 cmH₂O
Number of subjects: 18
Study 19496898 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily application of 0.1% tacrolimus
Number of subjects: 17
Study 19496898 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily application of 0.1% tacrolimus
Number of subjects: 17
Study 19496898 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated lesions)
Number of subjects: 17
Study 16330464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiplatelet plus moderate intensity anticoagulant therapy
Number of subjects: 311
Study 16330464 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy (target INR = 2.0-3.0)
Number of subjects: 311
Study 16330464 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant alone therapy
Number of subjects: 311
Study 14636087 — intervention group
Group type: EXPERIMENTAL
Intervention: High force warm-up routine (high % 1RM, low repetition squats)
Number of subjects: 32
Study 14636087 — intervention group
Group type: EXPERIMENTAL
Intervention: High power warm-up routine (low % 1RM, low repetition speed squats)
Number of subjects: 32
Study 14636087 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching warm-up routine (static stretches)
Number of subjects: 32
Study 14636087 — intervention group
Group type: COMPARATOR
Intervention: No activity (control condition)
Number of subjects: 32
Study 10751104 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training only (E)
Number of subjects: 45
Study 10751104 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 45
Study 10751104 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training only (S)
Number of subjects: 45
Study 10751104 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 45
Study 9156531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid transfusion (3 hours)
Number of subjects: 27
Study 9156531 — intervention group
Group type: COMPARATOR
Intervention: Slow transfusion (12 hours)
Number of subjects: 27
Study 1638377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline sclerotherapy
Number of subjects: 45
Study 1638377 — intervention group
Group type: COMPARATOR
Intervention: Simple evacuation
Number of subjects: 45
Study 6712367 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy for two to four months
Number of subjects: 23
Study 6712367 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone treatment
Number of subjects: 23
Study 6712367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone after spironolactone
Number of subjects: 23
Study 6712367 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted chlorthalidone treatment
Number of subjects: 23
Study 30075147 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session manualized caregiver intervention
Number of subjects: 93
Study 30075147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 93
Study 30183463 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (HRV-BF) using resonant breathing
Number of subjects: 54
Study 30183463 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 27923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg I.V. every 2 weeks for up to 1 year
Number of subjects: 660
Study 27923550 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for up to 1 year
Number of subjects: 660
Study 27923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 I.V. on days 1, 8, 29, and 36
Number of subjects: 660
Study 27923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 50 mg/m2 I.V. on days 1 to 5 and days 29 to 33
Number of subjects: 660
Study 25916335 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary nutritional supplement containing magnesium, riboflavin and Q10
Number of subjects: 130
Study 25916335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23998158 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + enamel matrix derivative (EMD)
Number of subjects: 12
Study 23998158 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) + connective tissue graft (CTG)
Number of subjects: 12
Study 21362086 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA supplementation
Number of subjects: 18
Study 21362086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19282313 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (treated with amiodarone for at least 3 months prior to cardioversion and continued long-term if SR was restored)
Number of subjects: 61
Study 19282313 — intervention group
Group type: COMPARATOR
Intervention: Rate control (beta blockers and/or digoxin to reduce heart rate to <80 bpm at rest and <110 bpm after walking)
Number of subjects: 61
Study 19282313 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 61
Study 19282313 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 61
Study 17272503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus antithymocyte globulin (ATG)
Number of subjects: 134
Study 17272503 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 134
Study 17272503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus ATG
Number of subjects: 134
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea meal diet (200 g/kg)
Number of subjects: 0
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea meal diet (100 g/kg)
Number of subjects: 0
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet (100 g/kg)
Number of subjects: 0
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet (200 g/kg)
Number of subjects: 0
Study 15484727 — intervention group
Group type: COMPARATOR
Intervention: Control diet (soy-wheat)
Number of subjects: 0
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet
Number of subjects: 0
Study 15484727 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 15484727 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 0
Study 12408203 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-centered program
Number of subjects: 0
Study 12408203 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one intervention
Number of subjects: 0
Study 12408203 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0
Study 9881990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 96
Study 9881990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 96
Study 8034831 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention methods
Number of subjects: 50
Study 8034831 — intervention group
Group type: COMPARATOR
Intervention: Parental monitoring
Number of subjects: 50
Study 2661658 — intervention group
Group type: EXPERIMENTAL
Intervention: cetraxate 200 mg four times daily
Number of subjects: 49
Study 2661658 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg two times daily
Number of subjects: 49
Study 29661156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) with cognitive training and vitamin D supplementation (3 × 10,000 IU/wk.)
Number of subjects: 200
Study 29661156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) with cognitive training and placebo
Number of subjects: 200
Study 29661156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) without cognitive training and vitamin D supplementation (3 × 10,000 IU/wk.)
Number of subjects: 200
Study 29661156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) without cognitive training and placebo
Number of subjects: 200
Study 29661156 — intervention group
Group type: COMPARATOR
Intervention: Balance and toning control (BAT) intervention
Number of subjects: 200
Study 28270229 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg every 4 months for five doses)
Number of subjects: 190
Study 28270229 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 190
Study 23572469 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental folder
Number of subjects: 1634
Study 23572469 — intervention group
Group type: COMPARATOR
Intervention: Expert valuation
Number of subjects: 1634
Study 23561636 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (Hexbio(®)) containing fructooligosaccharide, Bifidobacterium and Lactobacillus, consumed twice daily for 7 days
Number of subjects: 120
Study 23561636 — intervention group
Group type: COMPARATOR
Intervention: Placebo, consumed twice daily for 7 days
Number of subjects: 120
Study 21566547 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection cream containing glycerol, vaseline, and liquid paraffin, applied twice a day
Number of subjects: 54
Study 21566547 — intervention group
Group type: COMPARATOR
Intervention: Vaseline ointment, applied twice a day
Number of subjects: 54
Study 19481749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation
Number of subjects: 50
Study 19481749 — intervention group
Group type: COMPARATOR
Intervention: Tactile sensation cannulation
Number of subjects: 50
Study 16513607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 18F‐FET PET studies (0‐40 min after injection of 180 MBq of 18F‐FET)
Number of subjects: 45
Study 16513607 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to peak analysis
Number of subjects: 45
Study 16513607 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV90‐to‐background ratio for single‐frame evaluation of the early‐uptake phase
Number of subjects: 45
Study 16513607 — intervention group
Group type: COMPARATOR
Intervention: Standard method (SUVmax)
Number of subjects: 45
Study 16513607 — intervention group
Group type: COMPARATOR
Intervention: SUVmax‐to‐background ratio
Number of subjects: 45
Study 15351769 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg/d to 300 mg/d)
Number of subjects: 150
Study 15351769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11262672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopia (defined as best-corrected visual acuity of 6/9 or worse in the absence of any pathological cause)
Number of subjects: 4721
Study 11262672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic cases
Number of subjects: 4721
Study 11262672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic eyes
Number of subjects: 4721
Study 11262672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic group
Number of subjects: 4721
Study 11262672 — intervention group
Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 4721
Study 9244750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (DE)
Number of subjects: 208
Study 9244750 — intervention group
Group type: COMPARATOR
Intervention: Exercise electrocardiography (EE)
Number of subjects: 208
Study 9244750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination strategy of DE and EE
Number of subjects: 208
Study 8229497 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine plus lorazepam (30 mg/m2 chlorpromazine and 0.04 mg/kg lorazepam, both given intravenously)
Number of subjects: 25
Study 8229497 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine alone (30 mg/m2 given intravenously)
Number of subjects: 25
Study 8229497 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiemetic therapy
Number of subjects: 25
Study 7149452 — intervention group
Group type: EXPERIMENTAL
Intervention: Plugged telescoping catheter (PTC) brush
Number of subjects: 19
Study 7149452 — intervention group
Group type: COMPARATOR
Intervention: Single sheathed nonplugged catheter brush
Number of subjects: 19
Study 30946883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol dose (0.4 g/kg)
Number of subjects: 50
Study 30946883 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol dose (0.6 g/kg)
Number of subjects: 50
Study 30946883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29021119 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 69
Study 29021119 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-Education (PE)
Number of subjects: 69
Study 29021119 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 69
Study 26507388 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks supervised preoperative rehabilitation program
Number of subjects: 40
Study 26507388 — intervention group
Group type: COMPARATOR
Intervention: Hospital standard preoperative management
Number of subjects: 40
Study 23932671 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth position on the seat
Number of subjects: 0
Study 23932671 — intervention group
Group type: COMPARATOR
Intervention: Non-adherers (control group)
Number of subjects: 0
Study 20536371 — intervention group
Group type: EXPERIMENTAL
Intervention: von Langenbeck with intravelar veloplasty
Number of subjects: 673
Study 20536371 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow palate repair
Number of subjects: 673
Study 20536371 — intervention group
Group type: COMPARATOR
Intervention: Millard cheiloplasty
Number of subjects: 673
Study 20536371 — intervention group
Group type: COMPARATOR
Intervention: Spina lip repair
Number of subjects: 673
Study 20536371 — intervention group
Group type: COMPARATOR
Intervention: Age at palatoplasty (9 to 12 months or 15 to 18 months)
Number of subjects: 673
Study 19427572 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 0
Study 19427572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17719311 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (maximal tolerated doses)
Number of subjects: 314
Study 16271820 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored photos
Number of subjects: 0
Study 16271820 — intervention group
Group type: COMPARATOR
Intervention: Black and white (grey-scaled) photos
Number of subjects: 0
Study 16271820 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored drawings
Number of subjects: 0
Study 16271820 — intervention group
Group type: COMPARATOR
Intervention: Black and white (grey-scaled) drawings
Number of subjects: 0
Study 13677579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 120
Study 13677579 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study 10340913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day, administered for 21 days)
Number of subjects: 10
Study 10340913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide coadministration
Number of subjects: 10
Study 10340913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide administration
Number of subjects: 10
Study 7617861 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional fast spin-echo MR cholangiopancreatography
Number of subjects: 37
Study 2043220 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor); specific dosage and duration not mentioned.
Number of subjects: 0
Study 2043220 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no adverse metabolic effects reported.
Number of subjects: 0
Study 6178649 — intervention group
Group type: EXPERIMENTAL
Intervention: exogenous interferon alpha (Le) (3 x 10(6) IU/ml, 1 drop daily)
Number of subjects: 14
Study 6178649 — intervention group
Group type: COMPARATOR
Intervention: albumin
Number of subjects: 14
Study 31862195 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza HA vaccine (QIV)
Number of subjects: 270
Study 30712432 — intervention group
Group type: EXPERIMENTAL
Intervention: MADIT-RIT specific settings
Number of subjects: 232982
Study 30712432 — intervention group
Group type: COMPARATOR
Intervention: MADIT-RIT settings
Number of subjects: 232982
Study 30712432 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥185 beats per minute or delay ≥6 seconds
Number of subjects: 232982
Study 30712432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate cutoff programming
Number of subjects: 232982